HDFC MF and ADIA Lead Major ₹777 Crore Block Deal in Corona Remedies
A massive liquidity event unfolded in the pharmaceutical sector as Sepia Investments and Anchor Partners offloaded significant stakes in Corona Remedies Limited. This high-value block deal attracted a heavy-weight lineup of domestic and international institutional investors, signaling strong confidence in the company's long-term prospects.
Breakdown of the Mega Divestment
On June 17, 2026, the stock exchange witnessed a substantial transfer of ownership in Corona Remedies. The primary seller, Sepia Investments, divested 43,28,943 shares at a price of ₹1,730 per share, amounting to approximately ₹748.9 crore.
Adding to this exit, Anchor Partners also offloaded 1,61,861 shares at the same price point of ₹1,730, contributing an additional ₹28 crore to the transaction. In total, these two sellers collectively exited positions worth roughly ₹776.9 crore in the pharmaceutical major.
HDFC Mutual Fund Dominates the Buy Side
The transaction saw participation from twelve distinct institutional buyers, with HDFC Mutual Fund emerging as the most aggressive acquirer. By purchasing 24,50,000 shares, HDFC MF invested approximately ₹423.9 crore, effectively absorbing more than half of the total deal value.
The buy-side appetite was further bolstered by several other major players:
- Aditya Birla Sun Life Mutual Fund: Acquired 4,90,000 shares worth ₹84.8 crore.
- Aberdeen Asian Smaller Companies Investment Trust Plc: Bought 4,50,868 shares for roughly ₹78 crore.
- Invesco Mutual Fund: Picked up 2,89,017 shares valued at ₹50 crore.
- Aberdeen Standard Sicav I: Acquired 2,74,132 shares worth ₹47.4 crore.
Global Institutional Interest in Corona Remedies
Beyond domestic mutual funds, the deal highlighted significant interest from global sovereign wealth and international asset management firms. The Abu Dhabi Investment Authority (ADIA) participated in the deal, acquiring 39,130 shares worth approximately ₹6.8 crore.
他の注目すべき海外投資家には、2億5100万ルピーを投資したWhiteOak Capital Mutual Fundや、2億5700万ルピーを投じたIndia Acorn ICAV - Ashoka WhiteOak Emerging Markets Equity Fundなどが含まれます。また、Kotak Mahindra Mutual Fund（2億8000万ルピー）、Factory Mutual Insurance Company（1900万ルピー）、TCW White Oak Emerging Markets Equity Fund（330万ルピー）による小規模な参画も見られ、同株のバリュエーションに対する幅広い機関投資家のコンセンサスが示されました。
主なポイント
- 大規模な流動性イベント: Sepia InvestmentsとAnchor Partnersによる総売却額は、1株あたり1,730ルピーの価格で、約77億6900万ルピーに達しました。
- HDFC MFの圧倒的な地位: HDFC Mutual Fundは、42億3900万ルピーを投資して取引額の50%以上を占める、コーナーストーン・バイヤーとなりました。
- 多様な投資家層: 今回の取引では、インド国内の投資信託とADIAやAberdeenといったグローバルな大手企業がバランスよく混在しており、Corona Remediesに対する機関投資家の強い信頼を示しています。